Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has provided an update.
Circio Holding ASA announced new in vivo data showcasing the advantages of its circVec circular RNA technology, which offers a novel alternative for diseases less suitable for current approaches. The data indicates a 10-fold increase in potency for circVec AAV in cardiac applications, highlighting potential development opportunities in muscle and cardiac genetic diseases. This advancement positions Circio to explore further partnerships and development opportunities, aiming to establish circVec as a leading platform in tissue-specific gene therapy.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing circular RNA vector expression technology for next-generation nucleic acid medicine. Their proprietary circVec platform is designed for efficient biogenesis of multifunctional circular RNA inside cells, applicable in genetic medicine, cell therapy, and chronic disease. The platform has shown significantly enhanced and durable protein expression compared to traditional mRNA vector systems.
Average Trading Volume: 1,202,321
Current Market Cap: NOK55.52M
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.